Cargando…
The prognostic impact of the immune signature in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that retain their poor prognosis despite recent advances in their standard of care. As the involvement of the immune system against HNSCC development is well-recognized, characterization of the immune signature and the...
Autores principales: | Baysal, Hasan, Siozopoulou, Vasiliki, Zaryouh, Hannah, Hermans, Christophe, Lau, Ho Wa, Lambrechts, Hilde, Fransen, Erik, De Pauw, Ines, Jacobs, Julie, Peeters, Marc, Pauwels, Patrick, Vermorken, Jan Baptist, Smits, Evelien, Lardon, Filip, De Waele, Jorrit, Wouters, An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576890/ https://www.ncbi.nlm.nih.gov/pubmed/36268020 http://dx.doi.org/10.3389/fimmu.2022.1001161 |
Ejemplares similares
-
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020) -
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
por: Baysal, Hasan, et al.
Publicado: (2021) -
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021) -
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018) -
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)